Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from LTR Pharma Limited ( (AU:LTP) ).
LTR Pharma Limited has made significant strides in its operations during the quarter ending June 30, 2025. The company commenced nationwide pharmacy distribution of SPONTAN, achieved key development milestones for ROXUS with plans for a US market launch in the first half of 2026, and signed a collaborative agreement for OROFLOW, targeting a $4.5 billion global market for oesophageal motility disorders. These developments, along with the strengthening of their clinical leadership, underscore LTR Pharma’s potential to transform care in high-need therapeutic areas.
More about LTR Pharma Limited
LTR Pharma Limited is a company focused on improving men’s health through the clinical development and commercialization of innovative nasal spray treatments for erectile dysfunction, specifically SPONTAN and ROXUS.
Average Trading Volume: 497,648
Technical Sentiment Signal: Sell
For a thorough assessment of LTP stock, go to TipRanks’ Stock Analysis page.